NASDAQ Listing Done, Oculis Eyes Phase III Readouts
Decent Cash Position After SPAC Merger
Having taken the special purpose acquisition corporation route to list in the US, Switzerland's Oculis is waiting for some vital late-stage data, notably on OCS-01 for diabetic macular edema.
